Semaglutide injections are FDA-approved weight loss medication administered weekly by an subcutaneous injection( It is sold under the brand name of Wegovy). IVFusionMD delivers an all-in-one consultation, weight tracking, and semaglutide injections to you. IVFusionMD administers a semaglutide with B12. B12 is a water-solube vitamin. Low B12 is associated with overweight and obesity and higher body mass index ( BMI). B12 can help promote increase in metabolism and help promote fat loss. Our doctors will access if you are a candidate for this weight loss treatment.
Semaglutide is a medication that acts like a glucagon-like peptide-1. The glucagon-like peptide-1 is a natural hormone released by your intestinal epithelial endocrine L-cells. The release occurs about 30 minutes after a meal and targets an increase in insulin and also lowers glucagon secretion. This lowers the post meal blood sugar spike. It also signs the brain to regulate appetite and food consumption. Semaglutide injection was approved in 2017 by the FDA as diabetes medication called Ozempic and then in 2021 as a weight loss medication called Wegovy. Both Ozempic and Wegovy are semaglutide injectable medications.
The semaglutide injections are done under the skin or subcutaneously on your thigh, stomach area, or upper arm. The injections are given once a week and the dosages are tapered up over a course of 16 to 20 weeks. The maximum dosage is 2.4 mg weekly. A slow taper will reduce the chances of gastrointestinal side effects that may arise.
Most common side effects of the injection include:
A slow taper and customizing dosages is helpful with decreasing the chances of getting these side effects.
In the FDA trials for Wegovy, there were four 68-week trials that totalled 2,600 individuals on Wegovy and 1,500 individuals on placebo. 3 of the trials were double-blind, placebo-controlled, randomized and one had double-blind, placebo-controlled, and randomized to switch from treatment to placebo. In largest trial with adults without diabetes, individuals who received Wegovy lost an average of 12.4% of their initial body weight compared to individuals who received placebo. In another trial with adults with type two diabetes, patients on Wegovy lost 6.2% of their beginning body weight compared to those who received placebo.
In another study published in the New England Journal of Medicine, 1960 adults were studied in a double blind trial that lasted 68 weeks. Adults on the semaglutide injections lost 14.9% of their body weight vs -2.4% with placebo. Adults on the semaglutide injections also showed an improvement in cardiometabolic risk and physical functioning compared to adults on the placebo.
At any IVfusionMD location, you can get a consultation with our providers to discuss if semaglutide injections are right for you and your weight loss journey.
If you’d like to make an appointment for weight loss management, please book your appointment online or call IVFusionMD. We look forward to helping you with optimizing your wellness and health.